Anthropic’s Claude AI discovers new enzyme system in first wet lab breakthrough

According to Anthropic, Claude found the enzyme system after searching through a massive database of DNA sequences, with the involvement of human scientists limited to the initial prompt and subsequent lab work. The company said its AI worked through 210 million tokens over 21 hours, using nearly 950 Claude agents, before one identified an unusual repeating pattern in the data.

The discovery is the first output from Anthropic’s wet lab, which was established earlier this year to test Claude’s potential contributions to scientific research. The company has drawn comparisons between the new enzyme system and the machinery behind Crispr, a widely-used gene-editing tool.

The announcement comes as Anthropic prepares to go public, positioning the discovery as an early demonstration of Claude’s scientific utility.

Why This Matters

Anthropic’s first wet lab result demonstrates how AI can autonomously drive scientific discovery, potentially accelerating research in fields like genomics and biotechnology.
The comparison to Crispr suggests the enzyme system could have significant implications for gene editing, though further validation is needed.
With Anthropic heading toward an IPO, this breakthrough serves as a high-profile proof point for Claude’s commercial and research value.

Background

Anthropic, an AI safety and research company, launched a physical “wet lab” earlier in 2026 to test whether its AI models could generate real-world scientific insights when paired with laboratory facilities. The lab involves both AI agents and human scientists who perform follow-up experiments. This marks the first publicly announced result from that initiative.

Key Perspectives

Anthropic: The company frames the discovery as a milestone in autonomous AI-driven research, emphasizing that Claude acted independently in identifying the enzyme system from a massive DNA database. Skeptics in the scientific community: While the result is notable, independent verification will be crucial. Comparisons to Crispr are preliminary, and the practical utility of the enzyme system remains to be confirmed through peer-reviewed replication. Investors and market observers: The discovery strengthens Anthropic’s narrative about Claude’s capabilities beyond language tasks, potentially positioning the company for a higher valuation as its IPO approaches.

What to Watch

Publication of peer-reviewed findings detailing the enzyme system’s structure and function.
Whether other research groups can independently replicate or build upon the discovery.
How this breakthrough influences Anthropic’s IPO roadshow messaging and investor interest.

ZOTPAPER